Compass-logo-RGB-outlines.png
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
23 mai 2024 17h05 HE | Compass Therapeutics
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic...
Compass-logo-RGB-outlines.png
Compass Therapeutics Provides Corporate Update
05 janv. 2024 08h00 HE | Compass Therapeutics
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...
logo.jpg
CD137 Antibodies Clinical Trials Market Opportunity Insight
21 mars 2023 03h56 HE | KuicK Research
Delhi, March 21, 2023 (GLOBE NEWSWIRE) -- Advancement in cancer immunology and recent clinical evidence have suggested that there is an urgent need to move towards new immunotherapeutic approaches...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
21 mars 2022 08h00 HE | Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...